Patents by Inventor Lon Spada
Lon Spada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200069847Abstract: Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.Type: ApplicationFiled: November 4, 2019Publication date: March 5, 2020Inventors: Michael R. Robinson, Hui Liu, Patrick M. Hughes, Lon Spada, Alazar N. Ghebremeskel
-
Publication number: 20070059336Abstract: Biocompatible intraocular drug delivery systems include a anti-angiogenic therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent may be selected from the group consisting of anti-angiogenesis peptides, hormones and nucleic acid agents. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.Type: ApplicationFiled: February 27, 2006Publication date: March 15, 2007Applicant: Allergan, Inc.Inventors: Patrick Hughes, Thomas Malone, Gerald De Vries, Jeffrey Edelman, Wendy Blanda, Lon Spada, Peter Baciu, Scott Whitcup
-
Publication number: 20070031472Abstract: Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use.Type: ApplicationFiled: June 23, 2006Publication date: February 8, 2007Applicant: Allergan, Inc.Inventors: Glenn Huang, Thierry Nivaggioli, Lon Spada, Hiroshi Sugimoto, Wendy Blanda, James Chang, Orest Olejnik
-
Publication number: 20060243696Abstract: A plastic container closure includes a bottle having an open end with a circumferential bottle shoulder and a tip insertable into the bottle opened end with a tip shoulder overlaying the bottle shoulder. The compressible seal ring is provided and disposed between the bottle shoulder and the tip shoulder and a tip-covering cap engagable with the bottle and the cap compressed to the seal.Type: ApplicationFiled: April 27, 2005Publication date: November 2, 2006Inventors: Lon Spada, Scott Gerondale, John Dries
-
Publication number: 20060233860Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.Type: ApplicationFiled: March 31, 2006Publication date: October 19, 2006Applicant: ALLERGAN, INC.Inventors: James Chang, Lon Spada, Wendy Blanda, Werhner Orilla, James Burke, Patrick Hughes
-
Publication number: 20060182783Abstract: Biocompatible intraocular drug delivery systems include a anti-angiogenic macromolecular therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent contains a component selected from the group consisting of anti-angiogenesis peptides and nucleic acid agents. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.Type: ApplicationFiled: March 8, 2006Publication date: August 17, 2006Applicant: ALLERGAN, INC.Inventors: Patrick Hughes, Gerald Devries, Jeffrey Edelman, Wendy Blanda, Lon Spada, Robert Lyons
-
Publication number: 20060111680Abstract: A terminally sterilizable container includes a polypropylene bottle having a body with a manually squeezable sidewall and a thickness preventing water loss. The bottle body includes shoulders for providing autoclave produced pressure distribution and deformation resistance along with an elongated tips outfitted to a neck of the body and having a lumen therethrough with a drop dispensing orifice. A cap enclosed the elongated tip and includes enclosed with a nub for sealing the orifice to prevent autoclave produced pressure leaks.Type: ApplicationFiled: November 23, 2004Publication date: May 25, 2006Inventors: Lon Spada, Paul Butorac, Scott Gerondale
-
Publication number: 20060032873Abstract: A container system includes a squeeze bottle of a specific volume having a neck with an open end and a medicament disposed within the bottle. A tip is provided which is insertable into the open end of the squeezable bottle and includes an internal tapered nozzle with the nozzle having increased diameter toward a tip opening. A cap is provided for removable attachment to the bottleneck for sealing the tip opening and a shoulder formed in the bottle proximate the neck and disposed at an angle is provided in order to enhance bubbless flow of the medicament to the nozzle and facilitate tamper proof sealing of the cap.Type: ApplicationFiled: August 11, 2004Publication date: February 16, 2006Inventors: Scott Gerondale, Lon Spada, Paul Butorac
-
Publication number: 20050281861Abstract: Biocompatible intraocular drug delivery systems include a non-neurotoxic macromolecule therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The macromolecule therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent may be selected from the group consisting of anti-angiogenesis agents, ocular hemorrhage treatment agents, non-steroidal anti-inflammatory agents, growth factor inhibitors (such as VEGF inhibitors), growth factors, cytokines, antibodies, oligonucleotide aptamers, siRNA molecules and antibiotics.Type: ApplicationFiled: April 27, 2005Publication date: December 22, 2005Applicant: ALLERGAN, INC.Inventors: Patrick Hughes, Tom Malone, Gerald Devries, Jeffrey Edelman, Wendy Blanda, Lon Spada, Peter Baciu, Scott Whitcup
-
Publication number: 20050274744Abstract: A dispensing tip includes a body suitable for attachment to a dispensing bottle along with a nozzle having a lumen therethrough for flow of liquid formulation and an egress orifice which is in fluid communication with the lumen for the formation of droplets. A concave arcuate surface of revolution about the egress orifice is provided and depending therefrom for enhancing droplet separation from the egress orifice which in turn insures uniform droplet formation and dispensement.Type: ApplicationFiled: June 10, 2004Publication date: December 15, 2005Inventors: Lon Spada, Paul Butorac
-
Publication number: 20050244474Abstract: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.Type: ApplicationFiled: April 29, 2005Publication date: November 3, 2005Applicant: Allergan, Inc.Inventors: Glenn Huang, Thierry Nivaggioli, Lon Spada, Hiroshi Sugimoto, Wendy Blanda, James Chang, Orest Olejnik
-
Publication number: 20050244473Abstract: Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.Type: ApplicationFiled: April 29, 2005Publication date: November 3, 2005Applicant: ALLERGAN, INC.Inventors: Patrick Hughes, Lon Spada, Hiroshi Sugimoto, Wendy Blanda, James Chang
-
Publication number: 20050244475Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as posterior ocular conditions.Type: ApplicationFiled: April 29, 2005Publication date: November 3, 2005Applicant: ALLERGAN, INC.Inventors: Jeffrey Edelman, Patrick Hughes, Thomas Malone, Gerald DeVries, Joan-En Chang-Lin, Jane Shiah, Thierry Nivaggioli, Lon Spada, Wendy Blanda
-
Publication number: 20050211734Abstract: A closure for a dropper bottle includes a nozzle having a neck and a shoulder. The neck includes an aperture at an end thereof for dropwise dispensing of a liquid, and the shoulder includes an outstanding circumferential ring and threads disposed between the ring and the neck. A cap is provided with a top and an axially downwardly extending skirt. The top has a seat for sealably engaging the aperture, and the skirt has internal grooves for engaging the nozzle threads and an internal circumferential lip for sealably engaging the ring. The lip is spaced apart from the aperture for enabling simultaneous sealing of the aperture and the ring upon rotation of said cap onto said nozzle.Type: ApplicationFiled: March 24, 2004Publication date: September 29, 2005Inventors: Lon Spada, Paul Butorac